AstraZeneca to buy cancer drug firm for $440m
The deal between AstraZeneca’s MedImmune subsidiary and London-based Spirogen comes less than two months after MedImmune sealed a $500m deal to buy US cancer drug specialist Amplimmune.
Spirogen was formed in 2001 as a spin-out from a number of institutions, including University College London, with partial funding from Cancer Research UK. It is majority owned by private equity firm Auven Therapeutics.
Advertisement
Hide AdAdvertisement
Hide AdMedImmune is paying $200m up front for Spirogen, with a further payment of up to $240m depending on development progress.
The US-based company is also investing $20m in ADC Therapeutics, another oncology specialist in Auven’s portfolio, to collaborate on treatments.